Helmy Eltoukhy Sells 100,000 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Helmy Eltoukhy sold 100,000 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $126.30, for a total value of $12,630,000.00. Following the transaction, the chief executive officer directly owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. This represents a 4.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Guardant Health Stock Down 0.6%

NASDAQ:GH traded down $0.72 during trading hours on Monday, hitting $124.89. 2,213,881 shares of the stock were exchanged, compared to its average volume of 2,140,162. The company’s 50 day moving average is $99.39 and its two-hundred day moving average is $101.12. Guardant Health, Inc. has a twelve month low of $40.35 and a twelve month high of $134.28. The company has a market capitalization of $16.56 billion, a P/E ratio of -36.84 and a beta of 1.61.

Institutional Trading of Guardant Health

Large investors have recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at $27,000. Chesapeake Asset Management LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Guardant Health in the 4th quarter valued at $31,000. Elyxium Wealth LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at $35,000. Finally, Parallel Advisors LLC increased its position in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

GH has been the topic of several research reports. Canaccord Genuity Group upped their price objective on Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Leerink Partners upped their price objective on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, February 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Mizuho upped their price objective on Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Wolfe Research initiated coverage on shares of Guardant Health in a report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $139.80.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.